'Vitality biopharma' presentation slideshows

Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides

160 views • 10 slides

Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

148 views • 10 slides

Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides

140 views • 10 slides

Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

Vitality Biopharma, Inc., a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel which permits the Company to scale up activities at its facilities used for the development of novel cannabinoid pharmaceutical prodrugs.

146 views • 9 slides

Newly developed compounds limit psychoactivity and cognitive impairment and may be especially useful for pediatric appli

Vitality Biopharma, Inc. a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has created a library of proprietary glycosides of THC, the main psychoactive chemical found in cannabis or marijuana, which enable targeted delivery that reduces or eliminates psychoactivity when used in oral drug formulations.

144 views • 8 slides

Approval of cannaboside pharmaceutical research included review by FDA and California Research Advisory Panel

67 views • 2 slides

Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides

Cannabinoid pharmaceuticals now in development for inflammatory bowel disease and narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.

90 views • 2 slides

Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

Newly developed compounds limit psychoactivity and cognitive impairment and may be especially useful for pediatric applications

53 views • 2 slides